High discontinuation rates of semaglutide are observed in the US, Japan, and Denmark, driven by financial barriers and medication intolerance. Patients with chronic conditions, who would benefit most ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...
Add Yahoo as a preferred source to see more of our stories on Google. The author studied medicine in Japan.Courtesy of Vikram Madireddy Vikram Madireddy is a medical student who studied in the UK, ...
The proportion of male PBC patients in Japan nearly doubled from 12.4% to 20.6% between 2010 and 2021, while the mean age at diagnosis increased by approximately 5 years, suggesting PBC should no ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation ...
There is an extremely low rate of chronic obstructive pulmonary disease (COPD) diagnoses in Japan, particularly among patients with airflow obstruction, despite regular respiratory function tests. The ...
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results